Struggling pharmaceutical company Catalent secured a deal with activist investor Elliott Investment Management.
The company is the main contract manufacturer of Novo Nordisk's fast-growing weight loss drug, Wegovy, for which demand has outstripped supply in recent months.
Catalent shares have shed more than half their value over the past year, and are down two-thirds from their peak in September 2021.
